Jiangbo Pharmaceuticals, Inc.(fka JGBO)

[bigplay777]

To Bigplay777 from Crocker Coulson

Thank you for your concern.

I will let Elsa respond to your question regarding the interest payment.

I do not believe that the difficulty in transferring large sums should have any negative impact on the company’s migration to NASDAQ.

The company has not made any change to the guidance provided when they reported Q3 results of revenues of $111 to $116 million and operating income of 40 to 43 million.

Normally the company would not report updated guidance unless there was a material change to expectations before they report earnings in September.

I fully agree with your point on more frequent news updates and we will have a call to discuss this. However, sometimes the company may have periods of slow news even though operations are proceeding well.

You will be glad to hear that the company should have a busy fall having been invited to a number of conferences.

Thanks again for your support.

Crocker Coulson
President
CCG INVESTOR RELATIONS
1325 Avenue of the Americas
Suite 2800
New York, NY 10019

Direct: 646-213-1915

Mobile: [phone]

China Mobile: [phone]

HK mobile: [phone]

Blackberry: 323-350-2793

Fax: [phone]

[e-mail]

www.ccgir.com | www.ccgirasia.com

Download and subscribe to the China Rising Investor Newsletter at http://www.chinarisingnews.com